(Q41356235)

English

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

scientific article published on 20 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 September 2017

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response (English)

1 reference

Europe PubMed Central

29 September 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Asher A Chanan-Khan

1

1 reference

Europe PubMed Central

29 September 2017

Kasyapa Chitta

2

1 reference

Europe PubMed Central

29 September 2017

Noreen Ersing

3

1 reference

Europe PubMed Central

29 September 2017

Aneel Paulus

4

1 reference

Europe PubMed Central

29 September 2017

Aisha Masood

5

1 reference

Europe PubMed Central

29 September 2017

Taimur Sher

6

1 reference

Europe PubMed Central

29 September 2017

Abhisek Swaika

7

1 reference

Europe PubMed Central

29 September 2017

Paul K Wallace

8

1 reference

Europe PubMed Central

29 September 2017

Terry L Mashtare

9

1 reference

Europe PubMed Central

29 September 2017

Greg Wilding

10

1 reference

Europe PubMed Central

29 September 2017

Kelvin Lee

11

1 reference

Europe PubMed Central

29 September 2017

Myron S Czuczman

12

1 reference

Europe PubMed Central

29 September 2017

Ivan Borrello

13

1 reference

Europe PubMed Central

29 September 2017

Naveen Bangia

14

1 reference

Europe PubMed Central

29 September 2017

language of work or name

0 references

publication date

20 October 2011

1 reference

Europe PubMed Central

29 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

29 September 2017

155

1 reference

Europe PubMed Central

29 September 2017

457-467

1 reference

Europe PubMed Central

29 September 2017

4

1 reference

Europe PubMed Central

29 September 2017

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Autocrine and paracrine growth loops in chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

1 October 2017

Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

11 June 2018

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

11 June 2018

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

Lenalidomide-induced tumour flare reaction in mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

Acquired CD40-ligand deficiency in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

19 August 2018

In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3698616

4 November 2018

Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysis of fresh human B-lymphocyte-derived leukemia cells by interferon-activated natural killer (NK) cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22010965

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2011.08882.X

1 reference

Europe PubMed Central

29 September 2017

1 reference

Europe PubMed Central

29 September 2017

1 reference

Europe PubMed Central

29 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41356235&oldid=2096615446"